Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF

Idiopathic Pulmonary Fibrosis Clinical Trial

Official title:

A Twelve Week, Open-label, Randomised, Parallel-group Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Oral Nintedanib in Combination With Oral Pirfenidone, Compared to Treatment With Nintedanib Alone, in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02579603
• Other study ID #: 1199.222
• Secondary ID: 2015-000640-42
• Status: Completed
• Phase: Phase 4
• First received: October 16, 2015
• Last updated: January 17, 2018
• Start date: October 16, 2015
• Est. completion date: January 31, 2017

Study information

• Verified date: January 2018
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase IV, twelve week, open label, randomized, parallel group study to assess safety and tolerability of combined treatment with nintedanib and pirfenidone.

A secondary objective is to assess the exposure based on PK trough concentration values to nintedanib either given alone or in combination with pirfenidone and to assess the exposure of pirfenidone when combined with nintedanib.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 105
• Est. completion date: January 31, 2017
• Est. primary completion date: January 3, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion criteria:

• Written informed consent consistent with ICH-GCP(The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use- Good clinical practice) and local laws, signed prior to any study procedures being performed (including any required washout)

• Male or female patients aged greater than or equal to 40 years at visit 1

• Idiopathic Pulmonary Fibrosis (IPF) diagnosis, based upon the ATS (American Thoracic Society)/ERS (European Respiratory Society)/JRS (Japanese Respiratory Society)/ALAT (Latin American Thoracic Association) 2011 guideline and confirmed by the investigator based on chest high resolution computed tomography (HRCT) scan performed within 12 months of visit 1

• FVC (Forced vital capacity) greater than or equal to 50% of predicted normal at visit 1

Exclusion criteria:

• ALT (Alanine transaminase), AST (Aspartate aminotransferase)> 1.5 fold upper limit of normal (ULN) at visit 1

• Total bilirubin > 1.5 fold ULN at visit 1

• Relevant airways obstruction (i.e. pre-bronchodilator FEV1 (Forced Expiratory Volume in one second)/FVC <0.7) at visit 1

• History of myocardial infarction within 6 months of visit 1 or unstable angina within 1 month of visit 1

• Bleeding Risk: Known genetic predisposition to bleeding, Patients who require fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K antagonists, dabigatran, heparin, hirudin etc) or high dose antiplatelet therapy, History of haemorrhagic central nervous system event within 12 months prior to visit 1, History of haemoptysis or haematuria, active gastro-intestinal bleeding or ulcers and/or major injury or surgery within 3 months prior to visit 1, International normalised ratio (INR) > 2 at visit 1, Prothrombin time and partial thromboplastin time (PTT) > 150% of institutional ULN at visit 1

• Planned major surgery during the trial participation, including lung transplantation,major abdominal or major intestinal surgery.

• History of thrombotic event (including stroke and transient ischemic attack) within 12 months of visit 1

• Severe renal impairment (Creatinine clearance <30 mL/min calculated by Cockcroft-Gault formula at visit 1) or end-stage renal disease requiring dialysis

• Treatment with NAC (n-acetylcysteine), prednisone >15 mg daily or >30 mg every 2 days OR equivalent dose of other oral corticosteroids and/or fluvoxamine within 2 weeks of visit 2

• Treatment with azathioprine, cyclophosphamide, cyclosporine as well as any other investigational drug within 8 weeks of visit 2

• Previous treatment with pirfenidone

• Permanent discontinuation of nintedanib in the past due to Adverse Events considered drug-related

• Known hypersensitivity to nintedanib, pirfenidone, peanut or soya or to any of the excipients

• A disease or condition which in the opinion of the investigator may interfere with testing procedures or put the patient at risk when participating in this trial

• Alcohol or drug abuse which in the opinion of the treating physician would interfere with treatment

• Women who are pregnant, nursing, or who plan to become pregnant while in the trial

• Women of childbearing potential not willing or able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly5 for 28 days prior to and 3 months after nintedanib administration

• Patients not able to understand and follow study procedures including completion of self administered questionnaires without help

• Patients who require dose reduction and/or temporary interruption during the run-in period with nintedanib 150 mg bid

• Patients with underlying chronic liver disease (Child Pugh A, B or C hepatic impairment)

Related Conditions & MeSH terms

• Fibrosis
• Idiopathic Interstitial Pneumonias
• Idiopathic Pulmonary Fibrosis
• Pulmonary Fibrosis

Intervention

Drug:
• Nintedanib
Nintedanib 150mg bid
• Pirfenidone

Locations

Country	Name	City	State
Canada	St. Paul's Hospital	Vancouver	British Columbia
Canada	Concordia Hospital	Winnipeg	Manitoba
France	HOP Avicenne	Bobigny
France	HOP de la Cavale Blanche	Brest
France	HOP Louis Pradel	Bron cedex
France	HOP Calmette	Lille
France	HOP Pasteur	Nice
France	HOP Bichat	Paris
France	HOP Pontchaillou	Rennes
Germany	Klinik Donaustauf	Donaustauf
Germany	Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH	Essen
Germany	Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg	Heidelberg
Italy	A.O.U. Policlinico Vittorio Emanuele	Catania
Italy	Osp. S. Giuseppe Fatebenefratelli	Milano
Italy	A.O.U. Senese Policlinico Santa Maria alle Scotte	Siena
Netherlands	Sint Antonius Ziekenhuis	Nieuwegein
Netherlands	Erasmus Medisch Centrum	Rotterdam
United States	Lowcountry Lung and Crit Care	Charleston	South Carolina
United States	The Lung Research Center, LLC	Chesterfield	Missouri
United States	Western CT Medical Group, P.C.	Danbury	Connecticut
United States	Minnesota Lung Center	Minneapolis	Minnesota
United States	Vanderbilt University Medical Center	Nashville	Tennessee
United States	Tulane University Hospital and Clinic	New Orleans	Louisiana

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Countries where clinical trial is conducted

United States,  Canada,  France,  Germany,  Italy,  Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Patients With On-treatment Gastrointestinal (GI) AEs (SOC GI Disorders) From Baseline to Week 12	Percentage of patients with on-treatment gastrointestinal (GI) Adverse events (AEs) (SOC GI disorders) from baseline to week 12.; On-treatment AEs were defined as AEs with an onset from the first dose of randomised treatment up to the last dose of randomised treatment (inclusive).	Baseline to week 12
Secondary	Predose Plasma Concentrations at Steady State (Cpre,ss) of Nintedanib at Baseline, Weeks 2 and 4	Predose plasma concentrations at steady state (Cpre,ss) of nintedanib at baseline (Visit 3), Week 2 (Visit 4) and Week 4 (Visit 5)	baseline, prior to intake of study medication on week 2 and week 4
Secondary	Predose Plasma Concentrations at Steady State (Cpre,ss) of Pirfenidone	Predose plasma concentrations at steady state (Cpre,ss) of pirfenidone at Week 2 (Visit 4) and Week 4 (Visit 5)	Prior to intake of study medication on week 2 and week 4

External Links

•   Link